MASH风险基因型对resmetirom疗效的影响
本研究为MAESTRO-NASH III期试验的预设分析,纳入738例非肝硬化MASH患者,评估PNPLA3、HSD17B13等风险基因型对resmetirom疗效的影响。结果显示resmetirom在MASH缓解、纤维化改善、MRI-PDFF应答及生物标志物方面的获益不受这些风险基因型(单独或复合评分)显著影响。
要点
- resmetirom对MASH缓解和纤维化改善的疗效不受PNPLA3等风险基因型影响。
- 高风险基因型患者基线代谢危险因素(如2型糖尿病、高血压)频率更低。
- 研究样本量有限,不足以检测风险基因型对疗效的微小影响。
核心结论
- 在MAESTRO-NASH试验中,resmetirom对MASH、肝纤维化、MRI-PDFF和MASH生物标志物的效应未受常见MASH风险基因型显著影响。
研究设计与样本
- MAESTRO-NASH III期试验的预设分析,纳入738例同意DNA采集、完成全部基因分型且基线和第52周有肝活检的非肝硬化MASH患者。
主要发现
- 基线时,PNPLA3或HSD17B13高风险基因型患者较地风险基因型患者2型糖尿病和高血压等代谢危险因素频率更低。
- 交互分析和疗效评估显示,resmetirom在第52周对MASH缓解、肝活检纤维化改善、MRI-PDFF应答和生物标志物的正面效应在高风险基因型患者中相似。
- 上述效应独立于性别、西班牙裔 ethnicity 和代谢危险因素。
- 因样本量有限,研究不足以检测风险基因型对resmetirom疗效的微小影响。
临床怎么用
- 对于非肝硬化MASH患者,无论常见MASH风险基因型状态如何,resmetirom的疗效预期相似。
局限性
- 样本量有限,研究未把握检测风险基因型对resmetirom疗效的微小效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Resmetirom, a thyroid hormone receptor beta agonist, improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with non-cirrhotic MASH. Risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, MBOAT7, and SERPINA1 have been associated with altered susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD), MASH, fibrosis, cirrhosis, and/or hepatocellular carcinoma. We evaluated the impact of MASLD risk genotypes on baseline characteristics and the response to resmetirom vs. placebo with respect to MASH, fibrosis, MRI-proton density fat fraction (MRI-PDFF), and other biomarkers. METHODS: Testing the effects of MASLD risk genotypes or combinations of high-risk alleles on liver biopsy, MRI-PDFF, and biomarker responses to resmetirom was a pre-specified analysis in 738 patients enrolled in the MAESTRO-NASH phase III trial who consented to DNA collection, were genotyped for all genes, and had liver biopsies at baseline and Week 52. RESULTS: At baseline, patients with high-risk genotypes of PNPLA3 or HSD17B13 had a lower frequency of metabolic risk factors, including type 2 diabetes mellitus and hypertension, than patients with low-risk genotypes. Interaction analyses and efficacy assessments indicated that resmetirom had similar positive effects on MASH resolution, fibrosis improvement on liver biopsy, MRI-PDFF response, and biomarkers at Week 52 in MAESTRO-NASH patients with high-risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7, either individually or as part of a composite genetic risk score. These effects were independent of sex, Hispanic ethnicity, and metabolic risk factors. Due to the limited sample size, the study was not powered to detect small effects of risk genotypes on resmetirom efficacy. CONCLUSIONS: Resmetirom's effects on MASH, liver fibrosis, MRI-PDFF, and MASH biomarkers in the MAESTRO-NASH trial were not significantly impacted by the presence of common MASH risk genotypes. This suggests that resmetirom's mchanism of action is not affected by hepatic defects conferred by prominent MASH genetic risk pathways. IMPACT AND IMPLICATIONS: Resmetirom has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It leads to MASH resolution and improvement of fibrosis in patients with non-cirrhotic MASH. Patients with MASH have higher prevalence of certain genetic variants which can be associated with more severe disease. In this study we evaluated the relationship between the presence of select MASH risk genotypes (e.g. PNPLA3, TM6SF2, or HSD17B13) or the combined total of MASH genetic risk alleles on the response to resmetirom and placebo in 738 patients with non-cirrhotic MASH with serial liver biopsies at baseline and week 52. Within the limitation of study sample size, resmetirom's benefits on MASH resolution, fibrosis improvement and hepatic steatosis were independent of the presence of MASH genetic risk genotypes either alone or in combination. CLINICAL TRIAL NUMBER: NCT03900429.
引用
- Chalasani NP, Taub R, Mogg R, et al. Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis. J Hepatol. 2026. PMID: 42833311. doi:10.1016/j.jhep.2026.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。